Promoting the inclusion of vital-capacity data in the bronchodilator response.
作者信息
Ben Saad Helmi
机构信息
Laboratory of Physiology, Faculty of Medicine of Sousse, University of Sousse, Tunisia.
出版信息
Int J Chron Obstruct Pulmon Dis. 2017 Apr 24;12:1243-1245. doi: 10.2147/COPD.S138452. eCollection 2017.
Abstract
摘要
相似文献
1
Promoting the inclusion of vital-capacity data in the bronchodilator response.促进将肺活量数据纳入支气管扩张剂反应评估中。
Int J Chron Obstruct Pulmon Dis. 2017 Apr 24;12:1243-1245. doi: 10.2147/COPD.S138452. eCollection 2017.
2
Bronchodilator responsiveness: interpret with caution.支气管扩张剂反应性：谨慎解读。
Thorax. 2012 Aug;67(8):667-8. doi: 10.1136/thoraxjnl-2012-201966. Epub 2012 Jun 12.
3
Are GOLDen slumbers drug induced?金色梦乡是药物所致吗？
Am J Respir Crit Care Med. 2008 Jun 1;177(11):1291; author reply 1291-2. doi: 10.1164/ajrccm.177.11.1291a.
4
The role of bronchodilators in controlling COPD symptoms.支气管扩张剂在控制慢性阻塞性肺疾病（COPD）症状方面的作用。
Community Nurse. 2000 Jun;6(5):19-20.
5
[Long-acting bronchodilator agents are the choice in COPD. Keeping the airways open continuously].长效支气管扩张剂是慢性阻塞性肺疾病（COPD）的首选药物。持续保持气道通畅。
MMW Fortschr Med. 2007 Nov 22;149(47):54.
6
Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations.慢性阻塞性肺疾病的支气管扩张剂可逆性：应用及局限性。
Lancet Respir Med. 2013 Sep;1(7):564-73. doi: 10.1016/S2213-2600(13)70086-9. Epub 2013 Jun 18.
7
Criteria for bronchodilator response.支气管扩张剂反应的标准。
Chest. 2002 Dec;122(6):2263; author reply 2263-4. doi: 10.1378/chest.122.6.2263.
8
The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease.稳定期慢性阻塞性肺疾病对支气管扩张剂的容量反应
COPD. 2008 Jun;5(3):147-52. doi: 10.1080/15412550802092928.
9
Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease.羧甲司坦可改善慢性阻塞性肺疾病患者的生活质量。
J Am Geriatr Soc. 2007 Nov;55(11):1884-6. doi: 10.1111/j.1532-5415.2007.01373.x.
10
[Chronic obstructive pulmonary disease (COPD): diagnosis and treatment].[慢性阻塞性肺疾病（COPD）：诊断与治疗]
Dtsch Med Wochenschr. 2004 Mar 5;129(10):490-3. doi: 10.1055/s-2004-820537.
引用本文的文献
1
COPD in exclusive narghile smokers: Some points to verify.仅水烟吸食者中的慢性阻塞性肺疾病：一些需核实的要点。
Chron Respir Dis. 2017 Nov;14(4):420-421. doi: 10.1177/1479972317733863.
本文引用的文献
1
Measures of bronchodilator response of FEV, FVC and SVC in a Swedish general population sample aged 50-64 years, the SCAPIS Pilot Study.在瑞典50-64岁普通人群样本中，对FEV、FVC和SVC进行支气管扩张剂反应的测量，即SCAPIS试点研究。
Int J Chron Obstruct Pulmon Dis. 2017 Mar 22;12:973-980. doi: 10.2147/COPD.S127336. eCollection 2017.
2
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.慢性阻塞性肺疾病全球策略：诊断、管理与预防 2017 年报告。GOLD 执行摘要。
Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582. doi: 10.1164/rccm.201701-0218PP.
3
The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD.来自黄金标准的被遗忘的信息：用力肺活量（FVC）是慢性阻塞性肺疾病（COPD）中支气管扩张剂可逆性的主要临床结局指标。
Pulm Pharmacol Ther. 2008 Oct;21(5):767-73. doi: 10.1016/j.pupt.2008.04.005. Epub 2008 May 6.
4
[Spirometry reference values after inhalation of 200 microg of salbutamol].[吸入200微克沙丁胺醇后的肺量计参考值]
Arch Bronconeumol. 2007 Oct;43(10):530-4. doi: 10.1016/s1579-2129(07)60123-2.
5
Post-bronchodilator spirometry reference values in adults and implications for disease management.成人支气管扩张剂后肺量计参考值及其对疾病管理的意义。
Am J Respir Crit Care Med. 2006 Jun 15;173(12):1316-25. doi: 10.1164/rccm.200601-023OC. Epub 2006 Mar 23.
Zotero 插件